Central nervous system manifestations in systemic lupus erythematosus: Diagnosis to treatment

Autoimmune Diseases: Symptoms, Diagnosis and Treatment

Volumn , Issue , 2010, Pages 209-232

  Appenzeller, Simone ^a   Postal, Mariana ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85058587697     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (147)

1. West, SG. Neuropsychiatric lupus. Rheum Dis Clin North Am, 1994, 20, 129-158.
2. Hanly, JG; Walsh, NM; Sangalang, V. Brain pathology in systemic lupus erythematosus. J Rheumatol, 1992, 19, 732-741.
3. Johnson, RT; Richardson, EP. The neurological manifestations of systemic lupus erythematosus. Medicine, (Baltimore), 1968, 47, 337-369.
4. Hanly, JG. Neuropsychiatric lupus. Rheum Dis Clin North Am., 2005, 31, 273-98
5. Kozora, E; Arciniegas, DB; Filley, CM; et al. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol., 2005, 18, 159-62.
6. American College of Rheumatology (ACR) nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and Rheumatism, 1999, 42, 599-608.
7. Tan, EM; Cohen, AS; Fries, JF; et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25, 1271-7.
8. Ainiala, H; Hietaharju, A; Loukkola, J; et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum, 2001, 45, 419-423.
9. Ainiala, H; Loukkola, J; Peltola, J; Korpela, M; Hietaharju, A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology., 2001, 5, 496-500.
10. Brey, RL; Holliday, SL; Saklad, AR; et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology, 2002, 58, 1214-1220.
11. Afeltra, A; Garzia, P; Mitterhofer, AP; et al. Neuropsychiatric lupus syndromes, relationship with antiphospholipid antibodies. Neurology., 2003, 61, 108-10.
12. Hanly, JG; Fisk, JD; McCurdy, G; Fougere, L; Douglas, JA. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol., 2005, 32, 1459-6.
13. Sanna, G; Bertolaccini, ML; Cuadrado, MJ; et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol., 2003, 30, 985-92.
14. Mok, CC; Lau, CS; Wong, RW. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol, 2001,28, 766-71.
15. Hanly JG; McCurdy G; Fougere L et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance, J Rheumatol, 2004, 31, 2156-62.
16. Mikdashi J; Handwerger, B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology, (Oxford). 2004, 43, 1555-60.
17. Robert, M; Sunitha, R; Thulaseedharan, NK. Neuropsychiatric manifestations systemic lupus erythematosus: a study from South India. Neurol India., 2006, 54, 75-7.
18. Shimojima, Y; Matsuda, M; Gono, T; Ishii, W; Ikeda, S. Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clin Rheumatol., 2005, 24, 469-75
19. Estes, D; Christian, CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine, (Baltimore), 1971, 50, 85-95.
20. Feng, PH; Cheah, PS; Lee, YK. Mortality in systemic lupus erythematosus: a 10-year review. Br Med J., 1973, 4, 772-4.
21. Cheatum, DE; Hurd, ER; Strunk, SW; Ziff, M. Renal histology and clinical course of systemic lupus erythematosus. A prospective study. Arthritis Rheum., 1973, 16, 670-6.
22. Lee, P; Urowitz, MB; Bookman, AA et al. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med., 1977, 46, 1-32.
23. Ginzler, EM; Diamond, HS; Weiner, M et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum, 1982, 25, 601-611.
24. Sibley, JT; Olszynski, WP; Decoteau, WE; Sundaram, MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol, 1992, 19, 47-52.
25. Sergent, JS; Lockshin, MD; Klempner, MS; Lipsky, BA. Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. Am J Med., 1975, 58, 644-54.
26. Feinglass, EJ; Arnett, FC; Dorsch, CA; Zizic, TM; Stevens, MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine, (Baltimore). 1976, 55, 323-39.
27. Kovacs, JA; Urowitz, MB; Gladman DD. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am., 1993, 19, 795-814.
28. Jonsen, A; Bengston, AA; Nived, O; Rayberg, B; Sturfelt, G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology, 2002, 41, 1308-12.
29. Panopalis, P; Julian, L; Yazdany, J; Gillis, JZ; Trupin, L; Hersh, A; Criswell, LA; Katz, P; Yelin, E. Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum., 2007, 57, 1453-60.
30. Baker, K; Pope, J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology (Oxford). 2009, 48, 281-4.
31. Appenzeller, S; Cendes, F; Costallat, LT. Cognitive impairment and employment status in systemic lupus erythematosus: a prospective longitudinal study. Arthritis Rheum., 2009, 61, 680-7
32. Hanly, JG; Su, L; Farewell, V, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol., 2009, 36, 1449-59.
33. Carlomagno, S; Migliaresi, S; Ambrosone, L; Sannino, M; Sanges, G; Di Iorio, G. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol., 2000, 247, 273-9.
34. Karassa, FB; Ioannidis, JP; Boki, KA, et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med., 2000, 109, 628-34.
35. Appenzeller, S; Carnevalle, AD; Li, LM; Costallat, LT; Cendes F. Hippocampal atrophy in Systemic lupus erythematosus. Ann Rheum Dis., 2006, 65, 1585-9.
36. Hanly, JG; Fisk, JD; Sherwood, G; Eastwood, B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol, 1994, 2, 1825-31
37. Hay, EM; Huddy, A; Black, D et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis, 1994, 53, 298-303
38. Waterloo, K; Omdal, R; Husby, G; Mellgren, SI. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology, (Oxford), 2002, 41, 411-415.
39. Petri, M; Naqibuddin, M; Carson, KA et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol., 2008, 35, 2348-54
40. Brooks, WM; Jung, RE; Ford, CC et al. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol, 1999, 26, 81-85.
41. Appenzeller, S; Li, LM; Costallat, LT; Cendes, F. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain., 2005, 128, 2933-40.
42. Hanly, JG; Harrison, MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol., 2005, 19, 799-821.
43. Devinsky, O; Petito, CK; Alonso, DR. Clinical and neuropathological findings in systemic lupus erythematosus, the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol, 1988, 23, 380-384.
44. Ellis, SG; Verity, MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Sem Arthritis Rheum, 1979, 8, 212-221.
45. Zvaifler, NJ; Bluestein, HG. The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum, 1982, 25, 862-866.
46. Abbott, NJ; Mendonca, LL; Dolman, DE. The blood-brain barrier in systemic lupus erythematosus. Lupus., 2003, 12, 908-15.
47. Karpiak, SE; Graf, L; Rapport, MM. Antiserum to brain gangliosides produces recurrent epileptiform activity. Science., 1976, 194, 735-7.
48. Kobiler, D; Allweis, C. The effect of antisynaptosomal plasma membrane antibodies on memory. Brain Res., 1976, 115, 129-38.
49. Morris, RG; Anderson, E; Lynch, GS; Baudry, M. Selective impairment of learning and blockade of long-term potentiation by an Nmethyl- D-aspartate receptor antagonist, AP5. Nature, 1986, 319, 774-776.
50. Arinuma, Y; Yanagida, T; Hirohata, S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum., 2008, 58, 1130-5.
51. Akbarian, S; Sucher, NJ; Bradley, D et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci., 1996, 16, 19-30.
52. Teh, LS; Isenberg, DA. Antiribosomal, P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum, 1994, 37, 307-315.
53. Arnett, FC; Reveille, JD; Moutsopoulos, HM; Georgescu, L; Elkon, KB. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum, 1996, 39, 1833-1839.
54. Bonfa, E; Golombek, SJ; Kaufman, LD et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med, 1987, 317, 265-271.
55. Karassa, FB; Afeltra, A; Ambrozic, A et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum., 2006, 54, 312-24.
56. Tzioufas, AG; Tzortzakis, NG; Panou-Pomonis, E; et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Annals of Rheum Diseases, 2000, 59, 99-104.
57. Zandman-Goddard, G; Chapman, J; Shoenfeld, Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum., 2007, 36, 297-315
58. Hanly, JG. Antiphospholipid syndrome: an overview. Cmaj, 2003, 168, 1675-1682.
59. Gerli, R; Caponi, L; Tincani, A et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology, (Oxford). 2002, 41, 1357-66.
60. Love, PE; Santoro, SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med, 1990, 112, 682-698.
61. Menon, S; Jameson-Shortall, E; Newman, SP; Hall-Craggs, MR; Chinn, R; Isenberg, DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum, 1999, 42, 735-741.
62. Chapman, J; Cohen-Armon, M; Shoenfeld, Y; Korczyn, AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus, 1999, 8, 127-133.
63. Appenzeller, S; Zeller, CB; Annichino-Bizzachi, JM et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clinical Neurol and Neurourg, 2005, 107, 371-378.
64. Conti, F; Alessandri, C; Bompane, D et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for antiendothelial-cell Abs. Arthritis Res Ther, 2004, 6, 366-72.
65. Song, J; Park, YB; Lee, WK; Lee, KH; Lee, SK. Clinical associations of antiendothelial cell Abs in patients with systemic lupus erythematosus. Rheumatol Int, 2000, 20, 1-7.
66. Schenatto, CB; Xavier, RM; Bredemeier M et al. Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis., 2006,65, 829-31
67. Hirohata, S; Miyamoto, T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum, 1990, 33, 644-649.
68. Jara, LJ; Irigoyen, L; Ortiz, MJ; Zazueta, B; Bravo, G; Espinoza, LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol, 1998, 17, 110-114.
69. Trysberg, E; Carlsten, H; Tarkowski, A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus, 2000, 9, 498-503.
70. Shiozawa, S; Kuroki, Y; Kim, M; Hirohata, S; Ogino, T. Interferon-alpha in lupus psychosis. Arthritis Rheum, 1992, 35, 417-422.
71. Faber-Elmann, A; Sthoeger, Z; Tcherniack, A; Dayan, M; Mozes, E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol., 2002, 127, 393-398.
72. Ainiala, H; Hietaharju, A; Dastidar, P et al.Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis and Rheum, 2004, 50, 858-65.
73. Hirohata, S, Kanai, Y; Mitsuo, A; Tokano, Y; Hashimoto, H. Npsle Research Subcommittee. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol., 2009 Jul 12.
74. [Epub ahead of print]
75. Small, P; Mass, MF; Kohler, PF; Harbeck, RJ. Central nervous system involvement in SLE. Diagnostic profile and clinical features. Arthritis Rheum, 1977, 20, 869-878.
76. Trysberg, E; Nylen, K; Rosengren, LE; Tarkowski, A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis and Rheum, 2003, 48, 2881-87.
77. Appenzeller, S; Rondina, JM; Li, LM; Costallat, LT; Cendes, F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum., 2005, 52, 2783-9.
78. McCune, WJ; MacGuirre, A; Aisen, A; Gebarski, S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum, 1988, 31, 159-166.
79. Rovaris, M; Viti, B; Ciboddo, G et al. Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatry., 2000, 68, 170-7.
80. Sibbitt, WL; Jr Schmidt, PJ; Hart, BL; Brooks, WM. Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol., 2003, 30, 1983-9.
81. Cotton, F; Bouffard-Vercelli, J; Hermier, M et al. MRI of central nervous system in a series of 58 systemic lupus erythematosus (SLE) patients with or without overt neuropsychiatric manifestations. Rev Med Interne, 2004, 25, 8-15.
82. Peterson, PL; Howe, FA; Clark, CA; Axford, JS. Quantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus. Lupus, 2003, 12, 897-902.
83. Graham, JW; Jan, W. MRI and the brain in systemic lupus erythematosus. Lupus, 2003, 12, 891-6.
84. Csepany, T; Bereczki, D; Kollar, J; Sikula, J; Kiss, E; Csiba, L. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol, 2003, 250, 1348-54.
85. Jennings, JE; Sundgren, PC; Attwood, J; McCune, J; Maly, P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology, 2004, 46, 15-21.
86. Oku, K; Atsumi, T; Furukawa, S et al. Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatology, (Oxford) 2003, 12, 773-7.
87. Holliday, SL; Navarrete, MG; Hermosillo-Romo, D; Valdez, CR; Saklad, AR; Escalante, A; Brey, RL. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus., 2003, 12, 697-703.
88. Steens, SC; Admiraal-Behloul, F; Bosma, GP et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum., 2004, 50, 2877-81.
89. Vermeer, SE; Priens, ND; den Heijer, T; Hofman, A; Koudstaal, PJ; Breteler, MB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med, 2003, 348, 1215-22.
90. Appenzeller, S; Vasconcelos Faria, A; Li, LM; Costallat, LT; Cendes, F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol., 2008, 64, 635-43
91. Bosma, GP; Rood, MJ; Huizinga, TW; de Jong, BA; Bollen, EL; van Buchem, MA. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging. Arthritis Rheum., 2000, 43, 2428-36.
92. Bosma, GP; Rood, MJ; Zwinderman, AH; Huizinga, TW; van Buchem, MA. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum., 2000, 43, 48-54.
93. Moritani, T; Shrier, DA; Numaguchi, Y et al. Diffusion-weighted echo-planar MR imaging of CNS involvement in systemic lupus erythematosus. Acad Radiol., 2001, 8, 741-53.
94. Demaerel, P; De Ruyter, N; Maes, F; Velghe, B; Wilms, G. Magnetic resonance angiography in suspected cerebral vasculitis. Eur Radiol., 2004, 14, 1005-12.
95. Hanly, JG. Single photon emission computed tomography scanning in neuropsychiatric systemic lupus erythematosus. J Rheumatol., 1998, 25, 401-3.
96. Nossent, JC; Hovestadt, A; Schonfeld, DH; Swaak, AJ. Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum, 1991, 34, 1397-403.
97. Rubbert, A; Marienhagen, J; Pirner, K et al. Single-photon emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum, 1993, 36, 1253-62.
98. Rogers, MP; Waterhouse, E; Nagel, JS et al. I-23 iofetamine SPECT scan in systemic lupus erythematousus with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus, 1992, 1, 215-219.
99. Kovacs, JA; Urowitz, MB; Gladman, DD; Zeman, R. The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J Rheumatol, 1995, 22, 1247-53.
100. Sabet, A; Sibbitt, WL; Jr Stidley, CA; Danska, J; Brooks, WM. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke., 1998, 29, 2254-60.
101. de Certaines, JD; Bovee, WMMJ; Podo, F. Magnetic resonance spectroscopy in biology and medicine: functional and pathological tissue characterization., New York: Pergamon Press, 1992.
102. Rudkin, TM; Arnold, DL. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol., 1999, 56, 919-26.
103. Denburg, SD; Carbotte, RM; Denburg, JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum, 1994, 37, 1311-1320.
104. Barile, L; Lavalle, C. Transverse myelitis in systemic lupus erythematosus—the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol, 1992, 19, 370-372.
105. Eyanson, S; Passo, MH; Aldo-Benson, MA; Benson, MD. Methylprednisolone pulse therapy for nonrenal lupus erythematosus. Ann Rheum Dis, 1980, 39, 377-380.
106. Mok, CC; Lau, CS; Wong, RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med, 2003, 115, 59-62.
107. Barile-Fabris, L; Ariza-Andraca, R; Olguin-Ortega, L et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis., 2005, 64, 620-5.
108. Leung, FK; Fortin, PR. Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. J Rheumatol, 2003, 30, 1871-73.
109. Boumpas, DT; Yamada, H; Patronas, NJ; Scott, D; Klippel, JH; Balow, JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med., 1991, 81, 975-984.
110. Neuwelt, CM; Lacks, S; Kaye, BR; Ellman, JB; Borenstein, DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med, 1995, 98, 32-41.
111. Ramos, PC; Mendez, MJ; Ames, PR; Khamashta, MA; Hughes, GR. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol, 1996, 14, 295-299.
112. Mok, CC; Lau, CS; Chan, EY; Wong, RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol, 1998, 25, 467-473.
113. Galindo-Rodriguez, G; Avina-Zubieta, JA; Pizarro, S et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med, 1999, 106, 65-69.
114. McCune, WJ; Golbus, J; Zeldes, W; Bohlke, P; Dunne, R; Fox, DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med, 1988, 318, 1423-1431.
115. Khamashta, MA; Cuadrado, MJ; Mujic, F; Taub, NA; Hunt, BJ; Hughes, GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med., 1995, 332, 993-7.
116. Crowther, MA; Ginsberg, JS; Julian, J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med., 2003, 349, 1133-38.
117. Cuadrado, MJ; Khamashta, MA; Ballesteros, A; Godfrey, T; Simon, MJ; Hughes, GRV. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore), 2000, 79, 57-68.
118. Sanna, G; Bertolaccini, ML; Mathieu A. Central nervous system lupus: a clinical approach to therapy, Lupus, 2003, 12, 935-942.
119. Baca, V; Lavalle, C; Garcia, R et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol, 1999, 26, 432-439.
120. Harisdangkul, V; Doorenbos, D; Subramony, SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive highdose intravenous corticosteroid pulse treatment. J Neurol, 1995, 242, 326-331.
121. Chatham, WW; Kimberly, RP. Treatment of lupus with corticosteroids. Lupus, 2001, 10, 140-147.
122. Funauchi, M; Ohno, M; Nozaki, Y; Sugiyama, M; Kinoshita, K; Kanamaru, A. Intrathecal corticosteroids for systemic lupus erythematosus with central nervous system involvement. J Rheumatol, 2003, 30, 207-208.
123. Propper, DJ; Bucknall, RC. Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis, 1989, 48, 512-515.
124. Boumpas, DT; Yamada, H; Patronas, NJ; Scott, D; Klippel, JH; Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med, 1991, 81, 975-984.
125. Takada, K; Illei, GG; Boumpas, DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus, 2001, 10, 154-161.
126. Trevisani, VF; Castro, AA; Neves Neto, JF; Atallah, AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev, 2000, CD002265.
127. Sakic, B; Kolb, B; Whishaw, IQ; Gorny, G; Szechtman, H; Denburg, JA. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J Neuroimmunol, 2000, 111, 93-101.
128. Farrell, M; Sakic, B; Szechtman, H; Denburg, JA. Effect of cyclophosphamide on leukocytic in. ltration in the brain ofMRL/lpr mice. Lupus, 1997, 6, 268-274.
129. Sakic, B; Szechtman, H; Denburg, SD; Denburg, JA. Immunosuppressive treatment prevents behavioral de. cit in autoimmune MRL-lpr mice. Physiol Behav, 1995, 58, 797-802.
130. Schroeder, JO; Euler, HH. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol, 1989, 260, 203-213.
131. Kazatchkine, MD; Kaveri, SV. Immunomodulation of autoimmune and inflammatory diseases with intravenousimmune globulin. N Engl J Med, 2001, 345, 747-755.
132. Hughes, RA; Raphael, JC; Swan, AV; van Doorn, PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev, 2001, CD002063.
133. Sherer, Y; Levy, Y; Langevitz, P; Lorber, M; Fabrizzi, F; Shoenfeld, Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol, 1999,18, 170-173.
134. Tomer, Y; Shoenfeld, Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol, 1992, 10, 391-393.
135. Valesini, G; Priori, R; Francia, A et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol, 1994, 16, 313-321.
136. Dong, Y; Zhang, X; Tang, F; Tian, X; Zhao, Y; Zhang, F. Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus. Chin Med J, (Engl) 2001, 114, 764-766.
137. Hay, EM. Psychiatric disorder and cognitive impairment in SLE. Lupus, 1994, 3, 145-148.
138. Schantz, V; Oestergaard, LL; Junker, P. Shrinking spinal cord following transverse myelopathy in a patient with systemic lupus erythematosus and the phospholipid antibody syndrome. J Rheumatol, 1998, 25, 1425-1428.
139. Moore, PM; Isenberg, D. Therapy of neuro-psychiatric systemic lupus erythematosus. Rheumatol Europe, 1997, 26, 36-39.
140. Grisanti, M; Nader, A; Cacciuttolo, R. Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid syndrome: successful treatment with mycophenolate mofetil. Lupus, 2001, 10, S31.
141. Mathieu, A; Sanna, G; Mameli, A et al. Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus. Lupus, 2002, 11, 52-56.
142. Nwobi, O; Abitbol, CL; Chandar, J; Seeherunvong, W; Zilleruelo, G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol., 2008, 23, 413-9.
143. Tokunaga, M; Saito, K; Kawabata, D; Imura, Y; Fujii, T; Nakayamada, S; Tsujimura, S; Nawata, M; Iwata, S; Azuma, T; Mimori, T; Tanaka, Y. Efficacy of rituximab (anti- CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis., 2007, 66, 470-5.
144. Appenzeller, S; Costallat, LT. Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia., 2004, 24, 1024-30.
145. Appenzeller, S; Cendes, F; Costallat, LT. Epileptic seizures in systemic lupus erythematosus. Neurology., 2004, 63, 1808-12.
146. Cimaz, R; Meroni, PL; Shoenfeld, Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus., 2006, 15, 191-7.
147. D’Cruz, DP; Mellor-Pita, S; Joven, B; Sanna, G; Allanson, J; Taylor, J; Khamashta, MA; Hughes, GR. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol., 2004, 31, 280-5.